Your browser doesn't support javascript.
loading
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.
Lawitz, Eric; Buti, Maria; Vierling, John M; Almasio, Piero L; Bruno, Savino; Ruane, Peter J; Hassanein, Tarek I; Muellhaupt, Beat; Pearlman, Brian; Jancoriene, Ligita; Gao, Wei; Huang, Hsueh-Cheng; Shepherd, Aimee; Tannenbaum, Brynne; Fernsler, Doreen; Li, Jerry J; Grandhi, Anjana; Liu, Hong; Su, Feng-Hsiu; Wan, Shuyan; Dutko, Frank J; Nguyen, Bach-Yen T; Wahl, Janice; Robertson, Michael N; Barr, Eliav; Yeh, Wendy W; Plank, Rebeca M; Butterton, Joan R; Yoshida, Eric M.
Afiliación
  • Lawitz E; Texas Liver Institute, University of Texas Health San Antonio, San Antonio, TX, USA. Electronic address: lawitz@txliver.com.
  • Buti M; Hospital Universitari Vall d Hebron and CIBEREHD del Instituto Carlos III, Barcelona, Spain.
  • Vierling JM; Baylor College of Medicine, Advanced Liver Therapies, Houston, TX, USA.
  • Almasio PL; Biomedical Department of Internal and Specialized Medicine, University of Palermo, Palermo, Italy.
  • Bruno S; IRCCS Istituto Clinico Humanitas and Humanitas University, Rozzano, Italy.
  • Ruane PJ; Ruane Medical and Liver Health Institute, Los Angeles, CA, USA.
  • Hassanein TI; Southern California GI and Liver Centers, Coronado, CA, USA.
  • Muellhaupt B; University Hospital Zurich, Zurich, Switzerland.
  • Pearlman B; Atlanta Medical Center, Atlanta, GA, USA; Emory School of Medicine, Atlanta, GA, USA.
  • Jancoriene L; Vilnius University Hospital Santariskiu Klinikos, Centre of Infectious Diseases, Vilnius University, Vilnius, Lithuania.
  • Gao W; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Huang HC; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Shepherd A; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Tannenbaum B; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Fernsler D; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Li JJ; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Grandhi A; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Liu H; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Su FH; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Wan S; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Dutko FJ; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Nguyen BT; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Wahl J; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Robertson MN; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Barr E; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Yeh WW; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Plank RM; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Butterton JR; Merck & Co, Inc, Kenilworth, NJ, USA.
  • Yoshida EM; University of British Columbia, Vancouver, BC, Canada.
Lancet Gastroenterol Hepatol ; 2(11): 814-823, 2017 11.
Article en En | MEDLINE | ID: mdl-28802814
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Uridina / Hepatitis C Crónica / Cirrosis Hepática Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Gastroenterol Hepatol Año: 2017 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Uridina / Hepatitis C Crónica / Cirrosis Hepática Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Gastroenterol Hepatol Año: 2017 Tipo del documento: Article